What is Oviva?
Founded in 2014 and headquartered in Altendorf, Switzerland, Oviva provides a specialized digital health platform designed to improve patient outcomes for those suffering from obesity, diabetes, and food allergies. The company distinguishes itself by integrating medical nutritional therapy with professional dietitian support, delivered through a secure, accessible smartphone interface. This hybrid approach—offering both face-to-face sessions and remote digital support—positions Oviva as a critical infrastructure provider in the modern healthcare ecosystem, bridging the gap between clinical intervention and daily patient management.
How much funding has Oviva raised?
Oviva has raised a total of $313.8M across 5 funding rounds:
Seed
$800K
Series A
$12M
Series B
$21M
Series C
$80M
Series D
$200M
Seed (2016): $800K, investors not publicly disclosed
Series A (2017): $12M led by Partech Ventures, Albion Capital Group LLP, F-Prime Capital Partners, Walking Ventures, and Eight Roads Ventures
Series B (2020): $21M supported by Albion Capital Group, Earlybird, Partech, F-Prime Capital, MTIP, and Eight Roads Ventures
Series C (2021): $80M featuring Temasek, Albion Capital Group, Mtip, Sofina, Earlybird, F-Prime Capital Partners, and Eight Roads
Series D (2026): $200M backed by Lunate, EGS Beteiligungen, Planet First Partners, Temasek, Kinnevik, Sofina, Norrsken Vc, and AP Moller Group
Key Investors in Oviva
Lunate
Lunate is a leading alternative investment manager, headquartered in Abu Dhabi, with US$105 billion in assets under management.
EGS Beteiligungen
EGS Beteiligungen AG is a subsidiary of the Ernst Göhner Stiftung, focusing on long-term investments in Swiss-related companies and growth financing for late-stage technology startups.
Planet First Partners
Planet First Partners is a growth equity platform that invests in and collaborates with disruptive entrepreneurs to scale tech-enabled businesses focused on sustainable practices.
What's next for Oviva?
With the successful closure of this major strategic investment, Oviva is well-positioned to deepen its penetration in existing markets and explore new geographic territories. The company's focus will likely shift toward scaling its proprietary technology stack and expanding its network of professional dietitians to meet rising demand for digital therapeutics. By maintaining its commitment to evidence-based care, Oviva is poised to solidify its leadership in the healthtech space, potentially setting the stage for further institutional growth or future strategic partnerships within the broader healthcare industry.
See full Oviva company page
